UroToday.com - Ureaplasma urealyticum and Mycoplasma Hominis are members of a unique group of microorganisms commonly identified in the genital tract of women. With the onset of sexual intercourse the prevalence of Mycoplasma increases dramatically an isolation is strongly dependent on the number of sexual partners. Convincing evidence of an infection caused by genital Mycoplasma is not easy, because they usually are not isolated in pure culture, making the evaluation even more difficult. Dr. Stavroula Baka and colleagues from Athens, Greece evaluated the prevalence of U. urealyticum and M hominis in women presenting with chronic urinary symptoms, and the subsequent improvement, if any, of symptom severity and urinary frequency after appropriate therapy targeting these microorganisms.
Cardium Provides Update On Phase 2b Excellarate Clinical Study And Plans For Additional Tissue Repair Applications
Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) provided an update on the completion of their MATRIX Phase 2b clinical study and announced plans to provide detailed safety and efficacy data for their Excellarate(TM) product candidate around the end of September. The MATRIX trial, a prospective, randomized, double-blind, placebo-controlled study, has enrolled 124 diabetic patients with non-healing, lower extremity neuropathic ulcers. The companies also reported that results from the MATRIX clinical study are expected to be used to support additional studies and applications of Tissue Repair's Gene Activated Matrix(TM) or GAM(TM) technology for ulcers and other potential applications, including not only the repair of soft tissue injuries such as diabetic or pressure ulcers, but hard tissue injuries such as those affecting bone.
Androgen Receptor Expression In Prostate Cancer Cells Is Suppressed By Activation Of Epidermal Growth Factor Receptor And ErbB2
UroToday.com - In the online version of Cancer Research, a group of Harvard investigators report that the epidermal growth factor (EGF) receptor (EGFR) and tyrosine kinase ErbB2 can negatively regulate the androgen receptor (AR) in prostate cancer models. Previous studies suggest that EGFR and ErbB2 contribute to enhanced AR activity in the setting of castration-resistant prostate cancer (CRPC). While increased expression of EGFR and ErbB2 are reported in xenograft models, correlation in human samples is not consistent. This study sought to further clarify the interaction between EGFR and ErbB2 with AR. CaP cell lines studied included LNCaP, LAPC4, C4-2 and CWR22-Rv1.
UroToday.com - Paradigm shift; instead of having the robot all around the patient and weighing 800 kg., how about having the patient all around the robot and weighing only a few 100 mg? The pioneering work of Cadeddu at Southwestern Medical School with magnetically controlled intracorporeal robots and by Dmitry Oleynikov at the University of Nebraska with electrically tethered intracorporeal robots could change the entire face of LESS and of NOTES. Oleynikov and colleagues have developed a fixed-base camera that can be deployed through a small incision into the abdomen as well as a mobile, insertable robot capable of "rolling" onto an organ and taking a biopsy.
UroToday.com - Testicular cancer incidence appears to be increasing worldwide. Despite growing concern over this increase, many aspects of testicular cancer epidemiology remain puzzling. So far, science provides few answers for its etiology or the geographic and temporal discrepancies in its incidence. Unfortunately, further evidence about the causal factors for testicular cancer will not be quickly forthcoming. One reason for this lack of progress is a general problem in all cancer research, the long duration between exposure and diagnosis, often decades later. There are other more specific challenges as well: the rarity of the disease and the difficulty of obtaining unbiased reports of maternal pregnancy behavior.
Combined Androgen Blockade With Bicalutamide For Advanced Prostate Cancer: Phase 3 Long-term Survival Follow-up, Double-blind, Randomized Study
UroToday.com - Use of an anti-androgen with castration for the treatment of prostate cancer (CaP) is referred to as combined androgen blockage (CAB). Use of CAB has been assessed in over 30 studies and a meta-analysis suggests that when non-steroidal anti-androgens are used there is a survival benefit with risk of death reduced by 8%. In the journal Cancer, Professor Hideyuki Akaza and collaborators report on a multicenter, double-blind, controlled trial comparing CAB using the anti-androgen bicalutamide (80mg, the licensed dose for Japan) vs. castration alone. A total of 205 Japanese men with stage C/D CaP were recruited at 49 centers between 2000 and 2001.